Peer reviewed
A 12-Month Study of the GH-Releasing Compound MK-677 in Hip Fracture Recovery
Bach et al. (2002) 12-month Phase 2 trial (PMID 12004295) showing MK-677 improved functional status in elderly patients with hip fracture. Despite positive pharmacodynamic data, Merck did not advance MK-677 to FDA approval.
Journal of the American Geriatrics Society (PubMed)Published 2002-03-01Accessed 2026-07-01
Registry record
Source metadata
- Publisher
- Journal of the American Geriatrics Society (PubMed)
- Source type
- Peer reviewed
- Registry ID
pubmed-mk677-hip-fracture-2002
Interpretation boundary
What this record can and cannot establish
Inclusion in the registry is not endorsement. The record supports only the claims that fit its design, population, date, and scope. Company, media, and community records can document that a claim was made without proving the claim itself.